Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 12, Issue 9, 2010, Pages 806-814

  Rabol R ^a,b,c   Boushel, R ^a   Almdal, T ^c   Hansen, C N ^a   Ploug, T ^a   Haugaard, S B ^c   Prats, C ^a   Madsbad, S ^c   Dela, F ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Mitochondrial respiration; Pioglitazone; Rosiglitazone; Skeletal muscle; Type 2 diabetes

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; ADENOSINE DIPHOSPHATE; CITRATE SYNTHASE; CYTOCHROME C OXIDASE; GLIMEPIRIDE; GLUCOSE; GLUTAMIC ACID; INSULIN; MALIC ACID; METFORMIN; PIOGLITAZONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROSIGLITAZONE; SAPONIN; SUCCINATE DEHYDROGENASE (UBIQUINONE); SUCCINIC ACID; TRIACYLGLYCEROL; UBIQUINOL CYTOCHROME C REDUCTASE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; MITOCHONDRIAL RESPIRATION; MUSCLE BIOPSY; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN CONTENT; SKELETAL MUSCLE; WESTERN BLOTTING;

EID: 77955042456     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01237.x     Document Type: Article

References (40)

1. Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006, 15:243-250.
2. Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes (Lond) 2007, 31:1302-1310.
3. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
4. Coletta DK, Sriwijitkamol A, Wajcberg E. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 2009, 52:723-732.
5. Maeda N, Takahashi M, Funahashi T. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
6. Mayerson AB, Hundal RS, Dufour S. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002, 51:797-802.
7. Belfort R, Harrison SA, Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
8. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002, 277:25226-25232.
9. Norris SL, Carson S, Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Curr Diabetes Rev 2007, 3:127-140.
10. Miyazaki Y, Defronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008, 10:1204-1211.
11. Goldberg RB, Kendall DM, Deeg MA. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
12. Deeg MA, Buse JB, Goldberg RB. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007, 30:2458-2464.
13. Krentz A. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. Diabetes Metab Res Rev 2009, 25:112-126.
14. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005, 307:384-387.
15. Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsoe R, Dela F. Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. Diabetologia 2007, 50:790-796.
16. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002, 51:2944-2950.
17. Morino K, Petersen KF, Dufour S. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005, 115:3587-3593.
18. Mogensen M, Sahlin K, Fernstrom M. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2007, 56:1592-1599.
19. Phielix E, Schrauwen-Hinderling VB, Mensink M. Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes 2008, 57:2943-2949.
20. Rabol R, Boushel R, Dela F. Mitochondrial oxidative function and type 2 diabetes. Appl Physiol Nutr Metab 2006, 31:675-683.
21. Pagel-Langenickel I, Schwartz DR, Arena RA. A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 2007, 293:H2659-H2666.
22. Schrauwen-Hinderling VB, Mensink M, Hesselink MK, Sels JP, Kooi ME, Schrauwen P. The insulin-sensitizing effect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function. J Clin Endocrinol Metab 2008, 93:2917-2921.
23. Pagel-Langenickel I, Bao J, Joseph JJ. PGC-1alpha integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle. J Biol Chem 2008, 283:22464-22472.
24. Skov V, Glintborg D, Knudsen S. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. PLoS ONE 2008, 3:e2466.
25. Wiley SE, Murphy AN, Ross SA, van der GP, Dixon JE. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc Natl Acad Sci U S A 2007, 104:5318-5323.
26. Colca JR, McDonald WG, Waldon DJ. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 2004, 286:E252-E260.
27. Paddock ML, Wiley SE, Axelrod HL. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci U S A 2007, 104:14342-14347.
28. Dela F, Larsen JJ, Mikines KJ, Ploug T, Petersen LN, Galbo H. Insulin-stimulated muscle glucose clearance in patients with NIDDM. Effects of one-legged physical training. Diabetes 1995, 44:1010-1020.
29. Rabol R, Hojberg PM, Almdal T. Effect of hyperglycemia on mitochondrial respiration in type 2 diabetes. J Clin Endocrinol Metab 2009, 94:1372-1378.
30. Lowry OH, Passonneau JV. Some recent refinements of quantitative histochemical analysis. Curr Probl Clin Biochem 1971, 3:63-84.
31. Kiens B, Richter EA. Types of carbohydrate in an ordinary diet affect insulin action and muscle substrates in humans. Am J Clin Nutr 1996, 63:47-53.
32. Lowry OH, Passonneau JV. A Flexible System of Enzymatic Analysis 1972, New York, Academic Press
33. Bergmeyer HU. Methods of Enzymatic Analysis 1974, New York, Academic Press
34. Ploug T, van Deurs B, Ai H, Cushman SW, Ralston E. Analysis of GLUT4 distribution in whole skeletal muscle fibers: identification of distinct storage compartments that are recruited by insulin and muscle contractions. J Cell Biol 1998, 142:1429-1446.
35. Gnaiger E. Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology. Int J Biochem Cell Biol 2009, 41:1837-1845.
36. Larsen S, Ara I, Rabol R. Are substrate use during exercise and mitochondrial respiratory capacity decreased in arm and leg muscle in type 2 diabetes? Diabetologia 2009, 52:1400-1408.
37. Civitarese AE, Ukropcova B, Carling S. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 2006, 4:75-87.
38. Toledo FG, Menshikova EV, Azuma K. Mitochondrial capacity in skeletal muscle is not stimulated by weight loss despite increases in insulin action and decreases in intramyocellular lipid content. Diabetes 2008, 57:987-994.
39. Brunmair B, Staniek K, Gras F. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004, 53:1052-1059.
40. Yamauchi T, Kamon J, Minokoshi Y. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.